HIGHBuilt-inProduct / Revenue mix
65%
top-12 products
“10-K Item 1A: 'revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025'”
PFE · Concentration risk · 10-K extracted
Pfizer (PFE) concentration risks
Updated
The most significant concentration Pfizer discloses is top-12 products at 65%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Pfizer’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH1
MEDIUM1
LOW1
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
41%
international operations
“10-K Item 1: 'Revenues from operations outside the U.S. of $25.5 billion, $24.9 billion and $31.4 billion accounted for 41%, 39% and 53% of Total revenues in 2025, 2024 and 2023, respectively'”
LOWBuilt-in & outside partyProduct / Revenue mix
13%
Eliquis
“10-K Item 1A: 'Eliquis accounted for 13% of Total revenues in 2025'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's product portfolio carries a meaningful concentration at the top of the revenue stack: 12 products that each exceeded $1 billion in annual revenues collectively accounted for 65% of total revenues in 2025 — a high-share structural concentration that reflects the economics of large-molecule pharmaceuticals, where a small number of approved compounds drive the bulk of sales. The character is structural — the portfolio is diversified across therapeutic areas, but the revenue contribution is highly skewed toward the blockbuster tier. Within that group, Eliquis is the most prominently disclosed individual product, accounting for 13% of total revenues in 2025 — a low-share exposure on a per-product basis, consistent with a loss-of-exclusivity risk that is specific to that molecule's patent timeline and biosimilar entry schedule rather than a broader platform risk. Geographic diversity partially offsets the product concentration: revenues from operations outside the U.S. accounted for 41% of total revenues in 2025 — a medium-share structural exposure that provides some buffer against domestic pricing and reimbursement headwinds, though it introduces foreign-exchange translation risk and country-specific regulatory variability. Taken together, the profile is that of a large, diversified pharmaceutical company where the dominant investment consideration is the rate of new-product approvals relative to the pace of exclusivity losses on the existing blockbuster tier.
For the engine’s reasoning on PFE’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - General
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 2 | 1 | 0 | 3 |
| AMGN | Amgen Inc. | 2 | 0 | 0 | 2 |
| PFE● | Pfizer, Inc. | 1 | 1 | 1 | 3 |
| GILD | Gilead Sciences, Inc. | 1 | 1 | 0 | 2 |
| BMY | Bristol-Myers Squibb Company | 1 | 0 | 0 | 1 |
| BIIB | Biogen Inc. | 0 | 0 | 2 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.